![Andrew B. Cubitt](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Andrew B. Cubitt
Corporate Officer/Principal chez ATYR PHARMA, INC.
Postes actifs de Andrew B. Cubitt
Sociétés | Poste | Début | Fin |
---|---|---|---|
ATYR PHARMA, INC. | Corporate Officer/Principal | 01/09/2011 | - |
Historique de carrière de Andrew B. Cubitt
Anciens postes connus de Andrew B. Cubitt
Sociétés | Poste | Début | Fin |
---|---|---|---|
ANAPTYSBIO, INC. | Fondateur | 01/10/2005 | 01/07/2009 |
Corporate Officer/Principal | 01/10/2005 | 01/07/2009 | |
Aurora Biosciences Corp.
![]() Aurora Biosciences Corp. BiotechnologyHealth Technology Aurora Biosciences Corp. designs and develops proprietary drug discovery systems, services and technologies to the discovery of new medicine. It develops a proprietary ultra-high throughput screening platform that uniquely integrates innovative fluorescence chemistry, molecular biology, miniaturization, automation, and informatics. The company also provides assay development and screening services. Aurora was founded in 1995 and is located in San Diego, CA. | Corporate Officer/Principal | 01/01/1996 | 01/01/2002 |
AMBIT BIOSCIENCES CORP | Corporate Officer/Principal | - | - |
X-Ceptor Therapeutics, Inc.
![]() X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Corporate Officer/Principal | 01/01/2002 | - |
Formation de Andrew B. Cubitt
The University of Sheffield | Doctorate Degree |
University of Birmingham | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 6 |
Royaume-Uni | 3 |
Opérationnelle
Corporate Officer/Principal | 5 |
Doctorate Degree | 1 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 5 |
Consumer Services | 3 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
ATYR PHARMA, INC. | Health Technology |
ANAPTYSBIO, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Aurora Biosciences Corp.
![]() Aurora Biosciences Corp. BiotechnologyHealth Technology Aurora Biosciences Corp. designs and develops proprietary drug discovery systems, services and technologies to the discovery of new medicine. It develops a proprietary ultra-high throughput screening platform that uniquely integrates innovative fluorescence chemistry, molecular biology, miniaturization, automation, and informatics. The company also provides assay development and screening services. Aurora was founded in 1995 and is located in San Diego, CA. | Health Technology |
X-Ceptor Therapeutics, Inc.
![]() X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
Ambit Biosciences Corp.
![]() Ambit Biosciences Corp. Pharmaceuticals: MajorHealth Technology Ambit Biosciences Corp. develops pharmaceutical drugs. It engages in discovery, development and commercialization of small-molecule kinase inhibitors for the treatment of cancer. The firm provides drug to treat unmet medical needs in oncology, autoimmune and inflammatory diseases. The company was founded on May 17, 2000 and is headquartered in San Diego, CA. | Health Technology |
- Bourse
- Insiders
- Andrew B. Cubitt
- Expérience